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Abstract
Background: Currently, herniated nucleus pulposus (HNP) with radiculopathy and other preconditions are
regarded as relative or absolute contraindications for lumbar total disc replacement (TDR). In Switzerland it is left to
the surgeon’s discretion when to operate. The present study is based on the dataset of SWISSspine, a
governmentally mandated health technology assessment registry. We hypothesized that preoperative nucleus
pulposus status and presence or absence of radiculopathy has an influence on clinical outcomes in patients
treated with mono-segmental lumbar TDR.
Methods: Between March 2005 and April 2009, 416 patients underwent mono-segmental lumbar TDR, which was
documented in a prospective observational multicenter mode. The data collection consisted of perioperative and
follow-up data (physician based) and clinical outcomes (NASS, EQ-5D).
Patients were divided into four groups according to their preoperative status: 1) group degenerative disc disease
("DDD”): 160 patients without HNP and no radiculopathy, classic precondition for TDR; 2) group “HNP-No
radiculopathy": 68 patients with HNP but without radiculopathy; 3) group “Stenosis": 73 patients without HNP but
with radiculopathy, and 4) group “HNP-Radiculopathy": 132 patients with HNP and radiculopathy. The groups were
compared regarding preoperative patient characteristics and pre- and postoperative VAS and EQ-5D scores using
general linear modeling.
Results: Demographics in all four groups were comparable. Regarding the improvement of quality of life (EQ-5D)
there were no differences across the four groups. For the two main groups DDD and HNP-Radiculopathy no
differences were found in the adjusted postoperative back- and leg pain alleviation levels, in the stenosis group
back- and leg pain relief were lower.
Conclusions: Despite higher preoperative leg pain levels, outcomes in lumbar TDR patients with HNP and
radiculopathy were similar to outcomes in patients with the classic indication; this because patients with higher
preoperative leg pain levels benefit from a relatively greater leg pain alleviation. The group with absence of HNP
but presence of radiculopathy showed considerably less benefits from the operation, which is probably related to
ongoing degenerative processes of the posterior segmental structures. This observational multicenter study
suggests that the diagnoses HNP and radiculopathy, combined or alone, may not have to be considered as
absolute or relative contraindications for mono-segmental lumbar TDR anymore, whereas patients without HNP but
with radiculopathy seem to be suboptimal candidates for the procedure.
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As long as tissue engineering of the intervertebral disc
remains in its infancy [1,2] and interbody fusion in
younger patients stays under special scrutiny, there will
be ongoing enthusiasm for motion preserving procedures
as alternative treatment in degenerative disc disease
(DDD). Because of reported long convalescence periods
after spinal fusion and a presumed risk of adjacent level
degeneration, patients increasingly want to be informed
about total disc replacement (TDR) especially in case of a
herniated nucleus pulposus (HNP). Looking at the pub-
lished results for the classic posterior procedures such as
conventional discectomy, microdiscectomy and percuta-
neous measures for treating HNP we observe heteroge-
neous results. Reported re-operation rates up to 18% (0-
18%) depending on follow up interval [3,4] and persistent
back or leg pain in 6 to 43% [3] of cases emphasize the
necessity for clear-cut indications. However, the most
recent reasearch confirms good outcomes in patients
meeting specific inclusion criteria [5,6].
The aforementioned facts outline demands for a single
staged solution with sustainable long term results. Suc-
cess rates of only 75 to 80% for the classic posterior pro-
cedure (lumbar discectomy) might still be challenged [7].
The Food and Drug Administration (FDA) approved
the first TDR for the lumbar spine, the SB Charité/
DePuy Spine in October 2004 [8,9] followed by the
approval of the Synthes ProDisc-L in August 2006 [10].
Considering publications by TDR pioneers [11-13] and
studies leading to FDA approval, indications and contra-
indications for TDR were defined [8,14,15].
The generally accepted indications are:
Single-level DDD between L4-S1 confirmed by MRI,
CT and/or CT myelography
Discogenic low back pain at the segment to be oper-
ated concordant with pain during provocative discogram
Back and/or leg pain without neural compression
Age between 18 and 60 years
Unsuccessful conservative therapy of at least six
months duration [15]
Contraindications are determined as follows:
Central or lateral recess stenosis
Facet joint arthrosis
HNP with neural compression, spondylolisthesis and
spondylolysis
Scoliosis
Osteopenia
There are another about 50 contraindications accord-
ing to the work of Wong et al. [16].
However, the current literature presents only a few
studies dealing with the prevalence of indications and
contraindications for TDR. Huang et al. reviewed a sin-
gle-surgeon series of 100 consecutive lumbar patients
including solely 5 TDR cases [17]. Fras and Auerbach
presented a retrospective 15-months record review of
patients in a private clinic indicating that less than 5%
of 190 consecutive spine surgery patients were free of
contraindications, qualifying them to be potential candi-
dates for TDR [18]. Applying similar criteria Chin [15]
evaluated a population of a university outpatient clinic
reporting 5-9% of patients without contraindications.
This suggests the need for randomized controlled
trials (RCTs) comparing fusion techniques or posterior
techniques with motion preserving procedures, but their
implementation remains difficult because of various lim-
itations [10,19-22].
In the history of TDR development many biomechani-
cal concepts were brought up and drawbacks were seen
[23-25]. Early investigations about the Acroflex-Disc, for
example, revealed the problem of rubber-tears and
made an instant product withdrawal necessary. This has
caused a situation of uncertainty during a time of a
noticeable increase in usage of lumbar TDR. Finally, one
widely noticed article raising concerns [26] led the Swiss
Federal Office of Public Health to temporarily link the
reimbursement of TDR to participation in a Health
Technology Assessment (HTA) registry. Following the
governmental request for close monitoring of all TDR
procedures, a nationwide registry was implemented
according to the principle of “coverage with evidence
development” [27,28]. At the same time, when spine
surgery figures in the USA were increasing exponen-
tially, Deyo et al. called for rigorous post marketing sur-
veillance of adverse events for all new implants and
procedures [29,30]. Moreover, the ongoing investigations
i nt h eU S Ac o n c e r n i n gt h eu s eo fS BC h a r i t és e e mt o
justify these measures [31].
As a nationwide data collection project the SWISSspine
registry opened opportunities for investigations with a
potentially high external validity. Amongst the most
interesting topics were indications and contraindications
for lumbar TDR. In the framework of the registry it was
left to the surgeons’ discretion to operate on patients
with HNP and/or radiculopathy. Taking into account the
potentially wide range of cases and symptoms we
hypothesized that there are differences in outcomes
between patients with respect to the preoperative NP sta-
tus and the presence or absence of radiculopathy.
Furthermore complications and revision rates are dis-
played because we assumed to find differences in the
four groups based on different extents of decompression.
Methods
Between March 2005 and April 2009, 768 patients with
lumbar TDR were documented. The following implants
were used: ActiveL (Braun/Aesculap, Tuttlingen, Ger-
many); Dynardi (Zimmer, Warsaw, IN, USA); Maverick
(Medtronic Sofamor Danek, Memphis, TN, USA);
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C h a r i t é( D e P u yS p i n e ,R a y n h a m ,M A ,U S A ) .F o l l o w i n g
predefined criteria for surgery given by the Swiss Spine
Society SGS, the TDR was only implanted after an at
least 6 months unsuccsessful conservative therapy.
Inclusion criteria for the study were monosegmental
surgery and availability of a follow-up examination
between 1 and 3 years after surgery. According to the
inclusion criteria, 120 bisegmental patients and 188
patients who had not yet reached the 1 year follow-up
were excluded. Further, 27 excluded patients did not
have any follow-up records yet.
Consequently 433 patients with a mono-segmental inter-
vention were included in the current study. There were 174
(40%) male and 259 (59%) female patients with a mean age
of 41 years (SD 9.5 years; range 19 - 65 years) and 43 years
(SD 9 years; range 20 - 65 years), respectively. Each patient
h a ds i g n e di n f o r m e dc o n s e n ta n dc o m p l e t e dN A S Sa n d
EuroQol-5D questionnaires, which were stored in the
MEMdoc database at the University of Bern’s Institute for
Evaluative Research in Medicine (IEFM) [32-34]. Further-
more, clinical records for each patient were gathered by the
physicians. Mean follow-up time using the latest available
follow-up assessment between the 1
st and 3
rd postoperative
year was 1 year and 10 months (SD 8 months).
We compared four patient groups regarding the NP sta-
tus and presence or absence of radiculopathy (Table 1).
Radiculopathy was defined as sciatica (leg pain) with
sensory and/or motor deficit and was based on the pre-
operative examination as recorded by the surgeon.
The group “DDD” consisted of 160 (36.9%) patients
with neither HNP nor radiculopathy, which is the classic
precondition for TDR. There were 68 (15.7%) patients in
the group “HNP-No radiculopathy”.T h eg r o u p“Steno-
sis” comprised 73 patients (16.9%) without HNP but with
radiculopathy which we attributed to a recess stenosis or
reduced clearance of the foramen. Finally, group “HNP-
Radiculopathy” consisted of 132 (30.5%) patients with
both, HNP and radiculopathy. The latter could be con-
sidered as the group with the typical contraindication.
Patient based assessment
Pain was assessed using two separate visual analog
scales (VAS) for back- and leg pain, both located on the
NASS form. General quality of life was assessed using
EQ-5D [35,36]. In this cost-utility based instrument
values range from -0.6 (quality of life worse than death)
via 0 (quality of life equals death) to 1 (best possible
quality of life).
Statistical analysis
Descriptive statistics for patient characteristics were cal-
culated for each group. Comparisons between the
groups regarding patient characteristics as well as
achievement of minimum clinically relevant difference
(MCID) were performed using univariate logistic regres-
sions or analysis of variance, where applicable. Pre- and
postoperative values, as well as pre- to postoperative dif-
ferences of the four groups were compared using gen-
eral linear modeling. Thereby Bonferroni-Holm
adjustments were set to account for multiple testing
between the groups. As adjustment factors, the follow-
ing documented and potentially clinically relevant co-
variates were employed for all outcomes: gender
(female/male), age (continous variable), preoperative
pain medication (yes/no), intervertebral level of the
intervention (L2/3, L3/4, L4/5, L5/S1), pharmacologi-
cally treated depression (yes/no), type of work (seden-
tary, physical, housewife, retired, unemployed) and
working activity level (unable to work, 10-40%, 50-90%,
100%).
All statistical analyses were conducted using SAS 9.2
(SAS Institute Inc, Cary, NC).
The current analysis was conducted in conformity
with the Helsinki Declaration. It is based on a govern-
mentally mandated nationwide HTA evaluation registry
and therefore ethical approval was not necessary. All
patients, did, however, sign three documents explaining
the purpose of data collection and asking for informed
consent.
Results
There were no significant differences between the four
groups with respect to mean age, gender distribution,
types of work and work ability or preoperative medica-
tion and distribution of operated levels (Table 2).
VAS back pain
There were no significant differences between the
groups in preoperative back pain levels (Table 3).
Regarding postoperative back pain, the group “Steno-
sis” was different from the group “DDD” (p = 0.004)
from the group “HNP-No radiculopathy” (p = 0.014)
and from the group “HNP-Radiculopathy” (p = 0.031)
in that it had a higher mean back pain level. Accord-
ingly, the pain relief in the group “Stenosis” was differ-
e n tf r o mt h eg r o u p“DDD” (p = 0.003), from the group
“HNP-No radiculopathy” (p = 0.003), and borderline
Table 1 Group allocation
Description HNP Radiculopathy N
DDD classic precondition no no 160
HNP-No
radiculopathy
HNP only yes no 68
Stenosis recess stenosis no yes 73
HNP-Radiculopathy classic
contraindication
yes yes 132
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pathy” (p = 0.071) (Table 3). After adjustment for cov-
ariates, the group “Stenosis” was different from the
groups “DDD” (p = 0.001) and “HNP-Radiculopathy”
(p = 0.032), whereas the difference to the group
“HNP-No radiculopathy” was bordeline not significant
(p = 0.064).
A significantly higher proportion of patients in the
group “DDD” (84%) reached the MCID in pain relief of
18 points [37] than in the group “Stenosis” ( 6 0 . 6 % )( p=
0.002). The differences between the group “HNP-No
radiculopathy” (77.4%) and the group “Stenosis” (60.6%)
and between the group “HNP-Radiculopathy” (71.7%)
and the group “Stenosis” (60.6%) were not significant (p
= 0.16 and p = 0.54, respectively).
VAS leg pain
Differences in the preoperative VAS leg pain result from
group allocation (Table 3).
The “HNP-No rad.” group revealed unexpectedly high
preoperative leg pain levels but this symptom was
obviously well adressed with the procedure. In contrast
Table 2 Patient characteristics at baseline
DDD HNP-No rad. Stenosis HNP-Rad.
n = 160 (36.9%) n = 68 (15.7%) n = 73 (16.9%) n = 132 (30.5%) Group comparison (p-value)
Mean age (yrs.) 41.8 41.1 42.7 41.4 0.83
Age range (yrs.) 20-65 19-65 24-61 20-62 n.a.
Females (%) 66.3 52.9 54.8 58.3 0.15
Occupat. sedentary work (%) 29.8 31.2 26.5 31.4
Occupat. physical work (%) 48.6 50.8 52.9 55.1
Occupat. housewife (%) 13.9 16.4 14.7 9.3 0.59
Occupat. retired (%) 3.5 1.6 1.5 1.7
Occupat. unemployed (%) 4.2 0 4.4 2.5
Work capacity 100% (%) 71.2 81.8 58.2 69.5
Work capacity 50-90% (%) 11.4 12.7 27.3 17.1 0.37
Work capacity 10-40% (%) 3.8 0 3.6 1.9
Unable to work (%) 13.6 5.5 10.9 11.4
No preop. medication (%) 3.6 4.7 2.2 1.3
Preop. NSAIDs (%) 66.3 67.1 67.7 70.5 0.39
Preop. opiates (%) 30.1 28.2 30.1 28.2
L2/3 (%)* 1.3 0.8
L3/4 (%) 9.7 2.9 5.6 1.5
L4/5 (%) 47.1 39.7 45.8 48.5 0.10
L5/S1 (%) 41.9 57.4 48.6 49.2
*3 cases, not part of the analysis; n.a. - not analysed
Table 3 Outcomes
DDD HNP-No rad. Stenosis HNP-Rad.
Preop. back pain 70.2 72.5 67.8 68.1
Postop. back pain 28.1 27.3 41.8* 30.3
Back pain relief: unadjusted 42.2 45.2 26.0* 37.8
Back pain relief: adjusted 49.8 45.9 32.6* 45.2
Preop. leg pain 52.1 47.3 55.0 62.3*
Postop. leg pain 20.1 20.2 31.5* 23.9
Leg pain relief: unadjusted 31.7 27.1 23.5* 38.4
Leg pain relief: adjusted 34.7 33.4 21.8* 34.0
Preop. quality of life 0.326 0.371 0.336 0.350
Postop. quality of life 0.753 0.784 0.702 0.754
Improvement of quality of life: unadjusted 0.427 0.413 0.366 0.404
Improvement of quality of life: adjusted 0.317 0.321 0.271 0.299
Unadjusted and adjusted back and leg pain relief and improvement of quality of life are shown in each group. Asteriks marks the group which was significantly
different to another group in bold. As adjustment factors, gender, age, preoperative pain medication, intervertebral level of the intervention, pharmacologically
treated depression, type of work and working activity level were employed.
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other groups.
Preoperatively the group “DDD” was different from
the group “HNP-Radiculopathy” (p = 0.018) which had
the highest leg pain levels. Also, the group “HNP-No
radiculopathy” was different from the group “HNP-Radi-
culopathy” (p = 0.003). Regarding postoperative leg pain,
the group “DDD” was different from the group “Steno-
sis” (p = 0.022) which still had the highest mean leg
pain levels.
The group “Stenosis” was different from “HNP-Radi-
culopathy” (p = 0.023) regarding leg pain relief. After
adjustment of covariates the group “Stenosis” was differ-
ent from the group “DDD” (p = 0.026) and from the
group “HNP-Radiculopathy” (p = 0.040). In all scenarios
the “Stenosis” group had the lowest leg pain relief.
66.7% of patients in the group “DDD” reached the leg
pain relief MCID of 18 points [37]. In the group “HNP-
No radiculopathy” there were 56.5%, in the group “Ste-
nosis” 60.1% and in the group “HNP-Radiculopathy”
71.7% of patients who reached the MCID. None of the
intergroup comparions regarding the MCID in leg pain
were significant. If the group “DDD”, “HNP-No radicu-
lopathy” and “Stenosis” was compared with the group
“HNP-Radiculopathy” the p-values were 1, 0.25 and
0.77, respectively.
Quality of Life (EQ-5D)
There were no significant differences in pre- or post-
operative EQ-5D scores or in unadjusted or adjusted EQ-
5D score improvements between the groups (Table 3).
64.4% of patients in group “DDD” reached the MCID
of 0.25 EQ-5D points [37,38]. In the group “HNP-No
radiculopathy” there were 62.9%, in the group “Stenosis”
52.9% and in the group “HNP-Radiculopathy” 60.8% of
patients who reached the MCID. None of the intergroup
comparions regarding the MCID of EQ-5D were signifi-
cant. If the group “DDD”, “HNP-No radiculopathy” and
“HNP-Radiculopathy” was compared with the group
“Stenosis” the p-values were 0.65, 1 and 1, respectively.
Complication and revision rates
Eight revisions during the same hospital stay were docu-
mented; 4 in group “DDD” (2.5%), 1 in group “Stenosis”
(1.5%) and 3 in group “HNP-Radiculopathy” (2.3%). Rea-
sons for revisions were the documented intraoperative
complications. For one revison in group “DDD” the rea-
son was missing. Details can be seen in Table 4.
Additionally, when considering the postoperative per-
iod until the third follow-up year, there were 6 patients
in the group “DDD” (3.8%), 1 in group “HNP-No radi-
culopathy” (1.5%), 2 in the group “Stenosis” (2.7%), and
9p a t i e n t si nt h eg r o u p“HNP-Radiculopathy” (6.8%)
who were revised during an additional hospitalization. 2
out of 9 revised patients in the group “HNP-Radiculopa-
thy” were revised twice each.
Discussion
Based on several studies the FDA approved lumbar TDR
with some exclusion criteria and many authors consid-
ered herniated nucleus pulposus with neural compres-
sion as contraindication [39-41]. Others, however, like
Zigler et al. [21] described TDR as an option in these
patients. In general indications and contraindications
have never been consequently adapted to newer results.
With data based on widely used and validated out-
come instruments (EQ-5D, NASS-VAS) and on infor-
mation recorded by surgeons pre- and postoperatively
we can draw a relatively clear image of the impact of
TDR-surgery on patients’ quality of life.
Unfortunately this study, based on data from a case
series, cannot provide further information when to
perform simple discectomy or when to perform ante-
rior decompression combined with TDR, which has to
be regarded as a limitation. Apart from the debate
about the superiority of microdiscectomy versus stan-
dard limited laminotomy Weber showed good results
after 4 years for patients operated on lumbar disc her-
niation [42]. Latest findings are reported in several stu-
dies resulting from the SPORT (Spine Patient
Outcome Research Trial) and can confirm these results
[43,44].
This study hypothesized that there are outcome differ-
ences between the four patient groups defined by HNP
status and presence or absence of radiculopathy. We
found relatively homogenous extents of back pain relief
between three of the four study groups of which only
the group DDD had the classic indication for TDR. The
group “Stenosis” stands out with clinically relevant and
considerably lower back pain relief. Similarly, postopera-
tive leg pain levels were not significantly different
between the groups, with the exception of the “Stenosis”
group that showed the lowest relative leg pain allevia-
tion. These findings challenge some of the previous lim-
itations for TDR while confirming others.
There were no differences in complication rates. We
expected to find a higher number of dura lesions in
group HNP-Radiculopathy in which it is essential to go
Table 4 Complications.
DDD HNP-No rad. Stenosis HNP-Rad.
Blood vessel injury 3 1 2 6
Ureter injury - 1 - -
Vertebral body injury - - 1 -
Dura lesion - - - 1
Total (%) 3 (1.8%) 2 (2.9%) 3 (4.1%) 7 (5.3%)
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decompression.
Recent publications focus on TDR as a sound 21
st
century approach. Hopes and appraisals but even more
polemics can be found [26,45,46]. Ross et al. evaluated
226 SB Charité III disc implantations in 160 patients
concluding that “These poor results indicate that further
use of this implant is not justified” [47]. In contrast,
Mayer et al. and Siepe et al. described good results for
the ProDisc II even applying less invasive approaches
[48-50]. Since the alarming results of the Acroflex-Disc
study [51] and the ongoing US court cases concerning
the SB-Charité [31] the Swiss health care authorities
were reluctant to accept TDR as a safe and efficacious
therapy. Therefore, a nationwide registry was mandated
to closely monitor TDR in uncontrolled clinical settings
[28,52]. When SWISSspine was in its role-out phase
Mirza commented on important issues like polyethylene
debris, loosening, infection, and bone-implant interface
[53] and concluded that hopes for a cure of back pain
and a marketing bonanza must be held in check by
principles of fairness and responsibility and by the long-
term results [53].
Published reports like that of Chin et al. [15] sug-
gested that 95% of patients undergoing lumbar spinal
surgery had at least one contraindication for TDR.
These conclusions do, however, depend upon the defini-
tions of indications and contraindications for lumbar
TDR.
Those presented in this study, although based on the
current literature, are not universally accepted, like the
HNP with neural compression [21].
Indications and contraindications will continue to
evolve with the improved understanding of this proce-
dure. Changing them might allow conceivably more
patients to be considered for lumbar TDR [18]. Is this
desirable? The immediate perceived success obtained
with the BAK cage for symptomatic DDD created an
environment in which indications were also loosely
modified and suboptimal surgical candidates were stabi-
lized with accordingly poorer results. Few surgeons now
perform anterior lumbar interbody fusions with stand-
alone cages (ALIF), but this procedure is increasingly
being abandoned because surgeons have seen it fail fre-
quently [54,55]. This scenario should not be repeated
with lumbar TDR.
As lumbar discectomy is a classic procedure for lum-
bar disc herniation and has been shown to be effective
[42], lumbar TDR can currently not compete with the
reported longterm results [56]. In the short term per-
spective, however, the procedures seem to be equal. In
accordance to our clinical experience relief of leg pain is
a striking clinical factor in microdisectomy [44] as well
as in anterior decompression in combination with
lumbar TDR consistent to the findings in this study.
The indication group most severely drawing our atten-
tion to its comparably poor outcomes is the “Stenosis”
group. Despite being the second smallest patient group,
it still represents about 17% of cases. This group is
defined on the absence of HNP and radiculopathy rather
than on the presence of other degenerative processes
which makes a more precise description of the truly
underlying pathology difficult. We interpreted this con-
stellation as a recess and/or foraminal stenosis, and,
given the persisting postoperative back and leg pain
levels, a degeneration of the posterior bony structures in
the sense of a facet joint arthrosis with spondylogenic
pain is also very likely. Hence these above listed contra-
indications are rather confirmed by the “Stenosis” group
and lumbar TDR seems a suboptimal solution for these
types of patients.
SWISSspine is a prospective observational study of a
large cohort of TDR recipients. Using the latest available
follow-up record of each patient between the 1
st and 3
rd
followup years we found considerable differences
between patients with the typical indication for the pro-
cedure and other patients with contraindications like
recess stenosis or facet joint arthosis. On the other hand
HNP or radiculopathy proved as contraindications with
only minor negative influence on back and leg pain
relief. Although German and Foley compared the litera-
ture concerning both TDR and standalone ALIF trying
to identify parallels [57], they concluded that the given
obstacles are difficult to overcome.
To date ALIF seems to be the only direct comparator
for TDR but it is a weak one, especially regarding bio-
mechanics. The hurdles to overcome when creating and
running RCTs comparing TDR to ALIF are high, but it
was done by Geisler, Guyer, Blumenthal or McAfee
[19-21]. Their results showed a similar patient satisfac-
tion and a slight superiority for TDR in several socio-
economic areas such as work status and duration of
hospitalization. Studies comparing the various TDR
types are upcoming but still rare [58].
Our study has several limitations. The patient classifi-
cation is based on presence but also on complete
absence of HNP and radiculopathy leaving some room
for interpretation about the true source of the preopera-
tive symptoms. Besides, follow-up times are moderate
compared to other studies [11,48] and the investigation
is based on registry data. Therefore limitations have to
be considered in the analysis and interpretation of such
data. Invalid conclusions can result when insufficient
attention is paid to issues such as missing data, sources
of bias and data quality. There were no data collected
for sub-classifying the HNP and the definition of the
symptom ‘radiculopathy’ is widespread and examiners’
subjectivity has influence on that variable; in
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present or not. If it was indicated as present but no
HNP was seen, we interpreted this as reduced clearance
of the foramen causing radiculopathy. On the other
hand, a previous analysis revealed a very stable course
of postoperative back pain and an even ongoing further
improvement of leg pain until 400 days after surgery
[28].
Although no common definition of radiculophathy in
the literature can be found our own clinical experience
tells us that approximately one third of patients present-
ing with leg pain clearly fulfills criteria for radiculopathy,
one third shows mixed signs of radicular and pseudora-
dicular symptoms, and one third is clearly pseudoradicu-
lar. In the literature there is little information on this
issue. However, data collecti o ni nS W I S S s p i n ei sm u l t i -
centric and due to its setting the registry reaches a very
high level of representativeness, i.e. external validity and
the likelihood of selection bias of patients is low.
The adjustment of mean pain relief and improvement
of quality of life in the groups was performed based on
the documented variables. Other potentially relevant
clinical variables like smoking and duration of symp-
toms were not part of the already high documentation
burden for surgeons, accordingly not allowing for their
adjustment. However, only patients with at least 6
months of unsuccessful conservative treatment were
operated and documented.
Conclusions
Despite a HNP and preoperative radiculopathy short
term outcomes were similar to patients in the group
with the classic indication (DDD). Furthermore these
patients did not show inferior outcomes compared with
historical cohorts treated with posterior decompression
procedures. Patients with recess and/or lateral stenosis,
eventually accompanied by facet joint arthrosis showed
suboptimal outcomes. Consequently, some of the cur-
rent agreements on indications and contraindications
for lumbar TDA are challenged while others are con-
firmed and our findings should be validated in trials
with higher evidence levels.
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